美股市场个股详情
TPTX Turning Point Therapeutics
- 76.010
- 0.0000.00%
交易中 08/17 16:00 (美东)
38.06亿总市值-11000市盈率TTM
0.000最高价0.000最低价0股成交量0.000今开76.010昨收0.00成交额0.00%换手率亏损市盈率(静)5007.43万总股本76.01052周最高4.80市净率36.64亿流通值75.30052周最低--股息TTM4819.99万流通股141.300历史最高--股息率TTM0.00%振幅23.770历史最低--平均价1股每手
关于Turning Point Therapeutics公司
Turning Point Therapeutics Inc是一家处于临床阶段的生物制药公司，参与设计和开发分子靶向肿瘤疗法，以解决现有疗法的局限性。它拥有下一代酪氨酸激酶抑制剂（TKI）产品线，这些抑制剂针对TKI-naive和TKI预治疗患者的癌症遗传驱动因素。该公司的主要候选药物瑞波替尼正在进行的一项名为 TRIDENT-1 的1/2期试验中接受评估，该试验用于治疗ROS1+晚期非小细胞肺癌（NSCLC）患者和ROS1+、NTRK+或ALK+晚期实体瘤患者。
公司介绍
公司代码TPTX
公司名称Turning Point Therapeutics
发行价格18.00
CEODr. Athena Countouriotis, M.D.
所属市场纳斯达克
员工数量142
证券类型海外普通股
董事高管
- 姓名
- 职务
- 年薪
- Dr. Athena Countouriotis, M.D.
- Director, President and Chief Executive Officer
- 1526.22万
- Kumar Srinivasan
- Executive Vice President and Chief Business Officer
- --
- Siegfried Reich
- Executive Vice President and Chief Scientific Officer
- 573.96万
- Paolo Tombesi
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Andrew Partridge
- Executive Vice President and Chief Commercial Officer
- --
- Dr. Mohammad Hirmand, M.D.
- Executive Vice President and Chief Medical Officer
- --
- Kyri Van Hoose
- Vice President, Accounting
- --
- Annette North
- Executive Vice President, General Counsel and Secretary
- 307.68万
- Garry A. Nicholson
- Director
- 99.81万
- Dr. Simeon J. George, M.B.A.,M.D.
- Independent Director
- 41.31万
- Barbara W. Bodem
- Independent Director
- --
- Patrick C. Machado, J.D.
- Independent Director
- 41.91万
- Dr. Carol G. Gallagher,Pharm.D.
- Independent Director
- 40.96万
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅